ID: ALA1282

Max Phase: Approved

First Approval: 1997

Molecular Formula: C14H16N4

Molecular Weight: 240.31

Molecule Type: Small molecule

Representations

Synonyms (8): Aldara | Imiquimod | Tmx-101 | NSC-369100 | NSC-759651 | R-837 | S-26308 | S26308
Synonyms from Alternative Forms(8):

Trade Names(3): Aldara | Imiquimod | Zyclara

Canonical SMILES:  CC(C)Cn1cnc2c(N)nc3ccccc3c21

Standard InChI:  InChI=1S/C14H16N4/c1-9(2)7-18-8-16-12-13(18)10-5-3-4-6-11(10)17-14(12)15/h3-6,8-9H,7H2,1-2H3,(H2,15,17)

Standard InChI Key:  DOUYETYNHWVLEO-UHFFFAOYSA-N

Molecule Features

Natural Product: Yes

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: Yes

First In Class: No

Black Box: Yes

Chirality: Yes

Availability: Yes

Prodrug: No

Properties

Molecular Weight: 240.31

Molecular Weight (Monoisotopic): 240.1375

AlogP: 2.82

#Rotatable Bonds: 2

Polar Surface Area: 56.73

Molecular Species: NEUTRAL

HBA: 4

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 4

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 5.01

CX LogP: 2.65

CX LogD: 2.65

Aromatic Rings: 3

Heavy Atoms: 18

QED Weighted: 0.75

Np Likeness Score: -0.84

References

1. Hirota K, Kazaoka K, Niimoto I, Kumihara H, Sajiki H, Isobe Y, Takaku H, Tobe M, Ogita H, Ogino T, Ichii S, Kurimoto A, Kawakami H..  (2002)  Discovery of 8-hydroxyadenines as a novel type of interferon inducer.,  45  (25): [PMID:12459008] [10.1021/jm0203581]

2. Gerster JF, Lindstrom KJ, Miller RL, Tomai MA, Birmachu W, Bomersine SN, Gibson SJ, Imbertson LM, Jacobson JR, Knafla RT, Maye PV, Nikolaides N, Oneyemi FY, Parkhurst GJ, Pecore SE, Reiter MJ, Scribner LS, Testerman TL, Thompson NJ, Wagner TL, Weeks CE, Andre JD, Lagain D, Bastard Y, Lupu M..  (2005)  Synthesis and structure-activity-relationships of 1H-imidazo[4,5-c]quinolines that induce interferon production.,  48  (10): [PMID:15887957] [10.1021/jm049211v]

3. Moarbess G, Deleuze-Masquefa C, Bonnard V, Gayraud-Paniagua S, Vidal JR, Bressolle F, Pinguet F, Bonnet PA..  (2008)  In vitro and in vivo anti-tumoral activities of imidazo[1,2-a]quinoxaline, imidazo[1,5-a]quinoxaline, and pyrazolo[1,5-a]quinoxaline derivatives.,  16  (13): [PMID:18513976] [10.1016/j.bmc.2008.05.022]

4. Thomas A, Laxton C, Rodman J, Myangar N, Horscroft N, Parkinson T..  (2007)  Investigating Toll-like receptor agonists for potential to treat hepatitis C virus infection.,  51  (8): [PMID:17548497] [10.1128/aac.00268-07]

5. Deleuze-Masquefa C, Moarbess G, Khier S, David N, Gayraud-Paniagua S, Bressolle F, Pinguet F, Bonnet PA..  (2009)  New imidazo[1,2-a]quinoxaline derivatives: synthesis and in vitro activity against human melanoma.,  44  (9): [PMID:19278757] [10.1016/j.ejmech.2009.02.007]

6. Shukla NM, Malladi SS, Mutz CA, Balakrishna R, David SA..  (2010)  Structure-activity relationships in human toll-like receptor 7-active imidazoquinoline analogues.,  53  (11): [PMID:20481492] [10.1021/jm100358c]

7. PubChem BioAssay data set, 

8. Unpublished dataset, 

9. PubChem BioAssay data set, 

10. Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program. DrugMatrix in vitro pharmacology data, 

11. Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W..  (2011)  Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).,  7  (12): [PMID:22194678] [10.1371/journal.pcbi.1002310]

12. USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date, 

13. Shi C, Xiong Z, Chittepu P, Aldrich CC, Ohlfest JR, Ferguson DM..  (2012)  Discovery of Imidazoquinolines with Toll-Like Receptor 7/8 Independent Cytokine Induction.,  3  (6): [PMID:22837811] [10.1021/ml300079e]

14. PubChem BioAssay data set, 

15. Schiaffo CE, Shi C, Xiong Z, Olin M, Ohlfest JR, Aldrich CC, Ferguson DM..  (2014)  Structure-activity relationship analysis of imidazoquinolines with Toll-like receptors 7 and 8 selectivity and enhanced cytokine induction.,  57  (2): [PMID:24383475] [10.1021/jm4004957]

16. PubChem BioAssay data set, 

17. PubChem BioAssay data set, 

18. Mark Wenlock and Nicholas Tomkinson. Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds,  [10.6019/CHEMBL3301361]

19. WHO Anatomical Therapeutic Chemical Classification, 

20. British National Formulary (72nd edition), 

21. DrugMatrix,  [10.6019/CHEMBL3885881]

22. Teofilović NK, Bihi M, Stojković MR, Tumir LM, Ester K, Kralj M, Majhen D, Oršolić N, Lepur A, Vrbanec D, Markotić A, Dembić Z, Weber AN, Piantanida I, Vugrek O, Diken M, Knežević J..  (2017)  1-ethyl-3-(6-methylphenanthridine-8-il) urea modulates TLR3/9 activation and induces selective pro-inflammatory cytokine expression in vitro.,  27  (7): [PMID:28254484] [10.1016/j.bmcl.2017.02.048]

23. Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Afshari CA, Hamadeh HK..  (2013)  A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,  136  (1): [PMID:23956101] [10.1093/toxsci/kft176]

24. Larson P, Kucaba TA, Xiong Z, Olin M, Griffith TS, Ferguson DM..  (2017)  Design and Synthesis of N1-Modified Imidazoquinoline Agonists for Selective Activation of Toll-like Receptors 7 and 8.,  8  (11): [PMID:29152046] [10.1021/acsmedchemlett.7b00256]

25. Unpublished dataset, 

26. Franck Touret, Magali Gilles, Karine Barral, Antoine Nougairède, Etienne Decroly, Xavier de Lamballerie, Bruno Coutard.  (2020)  In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication,  [10.1101/2020.04.03.023846]

27. Bernhard Ellinger, Denisa Bojkova, Andrea Zaliani, Jindrich Cinatl, Carsten Claussen, Sandra Westhaus, Jeanette Reinshagen, Maria Kuzikov, Markus Wolf, Gerd Geisslinger, Philip Gribbon, Sandra Ciesek.  (2020)  Identification of inhibitors of SARS-CoV-2 in-vitro cellular toxicity in human (Caco-2) cells using a large scale drug repurposing collection,  [10.21203/rs.3.rs-23951/v1]

28. Katie Heiser, Peter F. McLean, Chadwick T. Davis, Ben Fogelson, Hannah B. Gordon, Pamela Jacobson, Brett Hurst, Ben Miller, Ronald W. Alfa, Berton A. Earnshaw, Mason L. Victors, Yolanda T. Chong, Imran S. Haque, Adeline S. Low, Christopher C. Gibson.  (2020)  Identification of potential treatments for COVID-19 through artificial intelligence-enabled phenomic analysis of human cells infected with SARS-CoV-2,  [10.1101/2020.04.21.054387]

29. Dolšak A, Švajger U, Lešnik S, Konc J, Gobec S, Sova M..  (2019)  Selective Toll-like receptor 7 agonists with novel chromeno[3,4-d]imidazol-4(1H)-one and 2-(trifluoromethyl)quinoline/ quinazoline-4-amine scaffolds.,  179  [PMID:31247373] [10.1016/j.ejmech.2019.06.030]

30. Maria Kuzikov, Elisa Costanzi, Jeanette Reinshagen, Francesca Esposito, Laura Vangeel, Markus Wolf, Bernhard Ellinger, Carsten Claussen, Gerd Geisslinger, Angela Corona, Daniela Iaconis, Carmine Talarico, Candida Manelfi, Rolando Cannalire, Giulia Rossetti, Jonas Gossen, Simone Albani, Francesco Musiani, Katja Herzog, Yang Ye, Barbara Giabbai, Nicola Demitri, Dirk Jochmans, Steven De Jonghe, Jasper Rymenants, Vincenzo Summa, Enzo Tramontano, Andrea R. Beccari, Pieter Leyssen, Paola Storici, Johan Neyts, Philip Gribbon, and Andrea Zaliani.  (2020)  Identification of inhibitors of SARS-Cov2 M-Pro enzymatic activity using a small molecule repurposing screen,  [10.6019/CHEMBL4495564]

31. Andrea Zaliani, Laura Vangeel, Jeanette Reinshagen, Daniela Iaconis, Maria Kuzikov, Oliver Keminer, Markus Wolf, Bernhard Ellinger, Francesca Esposito, Angela Corona, Enzo Tramontano, Candida Manelfi, Katja Herzog, Dirk Jochmans, Steven De Jonghe, Winston Chiu, Thibault Francken, Joost Schepers, Caroline Collard, Kayvan Abbasi, Carsten Claussen , Vincenzo Summa, Andrea R. Beccari, Johan Neyts, Philip Gribbon and Pieter Leyssen.  (2020)  Cytopathic SARS-Cov2 screening on VERO-E6 cells in a large repurposing effort,  [10.6019/CHEMBL4495565]

32. Ganta NM, Gedda G, Rathnakar B, Satyanarayana M, Yamajala B, Ahsan MJ, Jadav SS, Balaraju T..  (2019)  A review on HCV inhibitors: Significance of non-structural polyproteins.,  164  [PMID:30639895] [10.1016/j.ejmech.2018.12.045]

33. Hunt JR, Kleindl PA, Moulder KR, Prisinzano TE, Forrest ML..  (2020)  Further exploration of the structure-activity relationship of imidazoquinolines; identification of potent C7-substituted imidazoquinolines.,  30  (2): [PMID:31784317] [10.1016/j.bmcl.2019.126788]

34. Ellen Van Damme.  (2021)  Screening of ~5500 FDA-approved drugs and clinical candidates for anti-SARS-CoV-2 activity,  [10.6019/CHEMBL4651402]

35. Kettle JG,Alwan H,Bista M,Breed J,Davies NL,Eckersley K,Fillery S,Foote KM,Goodwin L,Jones DR,Käck H,Lau A,Nissink JW,Read J,Scott JS,Taylor B,Walker G,Wissler L,Wylot M.  (2016)  Potent and Selective Inhibitors of MTH1 Probe Its Role in Cancer Cell Survival.,  59  (6): [PMID:26878898] [10.1021/acs.jmedchem.5b01760]

36. Bernhard Ellinger, Justus Dick, Vanessa Lage-Rupprecht, Bruce Schultz, Andrea Zaliani, Marcin Namysl, Stephan Gebel, Ole Pless, Jeanette Reinshagen, Christian Ebeling, Alexander Esser, Marc Jacobs, Carsten Claussen, and Martin Hofmann-Apitius.  (2021)  HDAC6 screening dataset using tau-based substrate in an enzymatic assay yields selective inhibitors and activators,  [10.6019/CHEMBL4808148]

37. Talukdar A, Ganguly D, Roy S, Das N, Sarkar D..  (2021)  Structural Evolution and Translational Potential for Agonists and Antagonists of Endosomal Toll-like Receptors.,  64  (12.0): [PMID:34107682] [10.1021/acs.jmedchem.1c00300]

38. Sutherland JJ, Yonchev D, Fekete A, Urban L..  (2023)  A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.,  14  (1): [PMID:37468498] [10.1038/s41467-023-40064-9]

39. European Medicines Agency, 

Source

Source(13):

• Scientific Literature
• PubChem BioAssays
• Clinical Candidates
• FDA Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book)
• USP Dictionary of USAN and International Drug Names
• DrugMatrix
• AstraZeneca Deposited Data
• WHO Anatomical Therapeutic Chemical Classification
• British National Formulary
• SARS-CoV-2 Screening Data 2020-21
• IMI-CARE SARS-CoV-2 Data
• Fraunhofer HDAC6
• European Medicines Agency